Volume | 289,108 |
|
|||||
News | - | ||||||
Day High | 1.90 | Low High |
|||||
Day Low | 1.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Checkpoint Therapeutics Inc | CKPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.90 | 1.75 | 1.90 | 1.79 | 1.82 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,287 | 289,108 | $ 1.82 | $ 527,485 | - | 1.30 - 3.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:16 | formt | 500 | $ 1.80 | USD |
Checkpoint Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
42.11M | 23.53M | - | 103k | -51.85M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Checkpoint Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CKPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.09 | 2.11 | 1.75 | 1.92 | 508,039 | -0.29 | -13.88% |
1 Month | 1.42 | 2.12 | 1.38 | 1.73 | 449,919 | 0.38 | 26.76% |
3 Months | 2.29 | 2.355 | 1.38 | 1.79 | 389,155 | -0.49 | -21.40% |
6 Months | 2.31 | 3.62 | 1.36 | 2.09 | 678,811 | -0.51 | -22.08% |
1 Year | 2.78 | 3.62 | 1.30 | 2.12 | 472,536 | -0.98 | -35.25% |
3 Years | 26.00 | 46.40 | 1.30 | 17.58 | 631,895 | -24.20 | -93.08% |
5 Years | 43.40 | 53.762 | 1.30 | 21.89 | 614,021 | -41.60 | -95.85% |
Checkpoint Therapeutics Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). |